Merck KGaA Foresees Mid-2019 US Launch Of Oral MS Therapy Mavenclad

 
• By Sten Stovall
Nerve cells
Mavenclad Already has approval in Europe to treat highly active relapsing MS • Source: Shutterstock

More from Strategy

More from Business